
    
      This study will assess the safety, reactogenicity, immunogenicity and persistence of two
      formulations of GSK Biologicals' pneumococcal vaccine 2189242A [high dose (HD) or low dose
      (LD)] given as a 3-dose primary vaccination course during the first 6 months of life followed
      by a booster dose at 12-15 months of age when co-administered with Infanrix hexa™ and
      compared to the vaccination with Synflorix™ and with Prevnar 13™ similarly co-administered
      with the Infanrix hexa™ vaccine.
    
  